Nanomolar β-glucosidase and β-galactosidase inhibition by enantiomeric α-1-C-alkyl-1,4-dideoxy-1,4-imino-arabinitol derivatives
作者:Dong Zi、Ying-Ying Song、Tian-Tian Lu、Maki Kise、Atsushi Kato、Jun-Zhe Wang、Yue-Mei Jia、Yi-Xian Li、George W.J. Fleet、Chu-Yi Yu
DOI:10.1016/j.ejmech.2022.115056
日期:2023.2
but greatly improved their inhibitions of bovine liver β-glucosidase and β-galactosidase. Furthermore, epimerization of C-1′ configurations of compounds 18a-e clearly lowered their inhibition potency of bovine liver β-glucosidase and β-galactosidase. Notably, some of the α-1-C-alkyl DAB derivatives were also found to have potent human lysosome β-glucosidase inhibitions. In contrast, enantiomers of compounds
一系列具有芳基的α-1- C-烷基DAB(1,4-二脱氧-1,4-亚氨基-d-阿拉伯糖醇)和LAB(1,4-二脱氧-1,4-亚氨基-l-阿拉伯糖醇)衍生物取代基被设计为 broussonetine W ( 12 ) 的类似物,并作为糖苷酶抑制剂进行了测定。虽然 α-1- C-烷基 DAB 衍生物16的抑制谱与 broussonetine W ( 12 ) 的抑制谱具有良好的相关性,但在端芳基 ( 17a-f ) 或 C-1' 位置的羟基上引入取代基烷基链 ( 18a-e) 降低了它们的 α-葡萄糖苷酶抑制作用,但大大提高了它们对牛肝 β-葡萄糖苷酶和 β-半乳糖苷酶的抑制作用。此外,化合物18a-e的 C-1' 构型的差向异构化明显降低了它们对牛肝 β-葡萄糖苷酶和 β-半乳糖苷酶的抑制效力。值得注意的是,还发现一些 α-1- C6-烷基 DAB 衍生物具有有效的人溶酶体 β-葡萄糖苷酶抑制作用。相反,化合物18a-e和1'-